Moderna, Inc. — Director's Dealing 2025

May 1, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2025-04-30

Reporting Person: SAGAN PAUL (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-04-30	Stock Option (Right to Buy)	$28.54	A	25512	Acquired	2035-04-30	Common Stock (25512)	Direct

Footnotes

F1: This option will become fully vested and exercisable on the earlier of April 30, 2026, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.